Eversept Partners’s Karyopharm Therapeutics KPTI Stock Holding History

Eversept Partners’s Portfolio KPTI Stock Details KPTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.7M	Hold	276,174	–	–	0.14%	85
2026 Q1	$1.54M	Buy	+276,174	New	+$2.11M	0.08%	95
2025 Q3	–	Sell	-257,154	Closed	-$1.11M	–	95
2025 Q2	$1.11M	Hold	257,154	–	–	0.1%	61
2025 Q1	$962K	Buy	257,154 +117,904	+85%	+$1.01M	0.1%	51
2024 Q4	$1.41M	Sell	139,250 -230,609	-62%	-$2.79M	0.13%	58
2024 Q3	$4.6M	Buy	369,859 +37,380	+11%	+$465K	0.32%	41
2024 Q2	$4.33M	Sell	332,479 -1,942	-0.6%	-$32.2K	0.3%	49
2024 Q1	$7.57M	Buy	+334,421	New	+$5.86M	0.51%	35

Other funds holding KPTI

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

CCM

Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners's KPTI Position: Q2 2026 in Review

Eversept Partners held its Karyopharm Therapeutics (KPTI) position steady in Q2 2026 at 276,174 shares worth $2.7M. The position accounts for 0.14% of the portfolio, ranked #85.

Eversept Partners first reported a position in KPTI in Q1 2024 and has held it in 8 quarters since. The position peaked at $7.57M in Q1 2024. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

Eversept Partners held 276,174 shares of Karyopharm Therapeutics worth $2.7M as of Q2 2026.
Eversept Partners left its Karyopharm Therapeutics share count unchanged in Q2 2026.
Karyopharm Therapeutics made up 0.14% of Eversept Partners's portfolio in Q2 2026, its #85 holding.
Eversept Partners first reported a position in Karyopharm Therapeutics in Q1 2024 and has held it in 8 quarters since.
Eversept Partners's Karyopharm Therapeutics position peaked at $7.57M in Q1 2024.
97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.